Term ends Jun 7, 2031 · High confidence
20-year base term ends Jul 6, 2031
Jul 6, 2011
Jun 7, 2031
Feb 27, 2024
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. 0 of 1 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jul 6, 2011, when application PCT/US2011/043096, the earliest non-provisional in its chain, was filed (this one was filed Oct 27, 2021) | Jul 6, 2031 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 10,487,332, US 10,532,067, US 11,291,682, US 11,324,770, US 11,596,645, US 11,655,475, US 11,666,534, US 11,766,401, US 9,770,463, US 9,801,897) | capped to Jun 7, 2031 | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 0 of 1 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jun 7, 2031 | High confidence |
This family
| Application PCT/US2011/043096 | PCT application no patent term | no patent term |
| US 10,487,332 | In force Jul 2031 | Jul 2031 |
| US 11,655,475 | In force Jun 2031 | Jun 2031 |
| US 11,913,001 | this patent Jun 2031 | Jun 2031 |
| US 11,739,334 | In force Jun 2031 | Jun 2031 |
| US 11,773,395 | In force Jun 2031 | Jun 2031 |
| US 11,845,925 | In force Jun 2031 | Jun 2031 |
| US 11,851,660 | In force Jun 2031 | Jun 2031 |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Sep 20, 2022 Reel 61145, frame 788 | Geall, Andrew | Novartis Vaccines and Diagnostics | Assignment of Assignor's Interest |
| Sep 20, 2022 Reel 61145, frame 833 | Novartis Vaccines and Diagnostics | Novartis AG | Assignment of Assignor's Interest |
| Sep 20, 2022 Reel 61145, frame 882 | Novartis AG | GlaxoSmithKline Biologicals S.A. | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
This term is capped by a terminal disclaimer resolved from the filed document, referencing US 10,487,332, US 10,532,067, US 11,291,682, US 11,324,770, US 11,596,645, US 11,655,475, US 11,666,534, US 11,766,401, US 9,770,463, US 9,801,897.